Showing results (411-420 of 488) with videos related to
Sort By:
Pageof 49
Journal of the American Geriatrics Society|March 26, 2021
Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A studySergio Salmerón Ríos, Marta Mas Romero, Elisa Belén Cortés Zamora, et al.Pharmacological Reviews|March 27, 2025
Cell cycle dysregulation in cancerAntonino Glaviano, Samarendra K Singh, E Hui Clarissa Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2023
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 TrialCorey W Speers, W Fraser Symmans, William E Barlow, et al.JCO Precision Oncology|December 1, 2021
Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic DiseaseKaren Page, Luke J Martinson, Daniel Fernandez-Garcia, et al.Breast Cancer Research and Treatment|June 7, 2021
Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patientsGeorgios Nteliopoulos, Karen Page, Allison Hills, et al.Journal for Immunotherapy of Cancer|December 23, 2025
Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancerRebecca Porter, Bruno Bockorny, Bradley R Corr, et al.Cancer Cell|July 12, 2011
A Pin1/mutant p53 axis promotes aggressiveness in breast cancerJavier E Girardini, Marco Napoli, Silvano Piazza, et al.Cancer|April 20, 2021
Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancerBeatriz E Adrada, Rosalind Candelaria, Stacy Moulder, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic SarcomasBreelyn A Wilky, Gary K Schwartz, Michael S Gordon, et al.The Journal of Pathology. Clinical Research|February 23, 2021
Variability in grading of ductal carcinoma in situ among an international group of pathologistsMaartje van Seijen, Katarzyna Jóźwiak, Sarah E Pinder, et al.Pageof 49